Company: TAK
Filing Date: 2025-06-25
Form Type: 20-F
Source: 0001395064-25-000095
Chunk: 163

Company: TAKEDA PHARMACEUTICAL CO LTD
Filing Date: 2025-06-25
Form: 20-F
Item: Item 8
Chunk 163
---
Item 8. Financial Information

A. Consolidated Statements and Other Financial Information

Our audited consolidated financial statements are included under “ Item 18 - Financial Statements.”

Legal Proceedings

The information required by this item is set forth in our consolidated financial statements included in this annual report. See Note 32 to our audited consolidated financial statements for a detailed discussion of legal proceedings.

Dividends

Takeda’s policy in the allocation of capital is as follows:

•Invest in growth drivers; and

• Shareholder returns.

With respect to "Invest in growth drivers", Takeda makes strategic investments in internal and external opportunities to enhance its pipeline, new product launches, and plasma-derived therapies. With regard to "Shareholder returns", Takeda has adopted a progressive dividend policy of increasing or maintaining the annual dividend per share each year, alongside share buybacks when appropriate.

As noted above, the return of capital to shareholders is one of the focus areas for our management, and we believe our dividend policy is an important tool for accomplishing our goals.

The following table sets forth the dividends paid with respect to each of our fiscal years indicated.

  Dividends declared and paid            JPY (billions)      Dividends per share JPY      Record date             Effective date    
                                        Total dividends                                                                             
  April 1, 2022, to March 31, 2023                                                                                                  
  Q1 2022                                             ¥                            ¥      March 31, 2022          June 30, 2022     
  Q3 2022                                         140.5                        90.00      September 30, 2022      December 1, 2022  
  April 1, 2023, to March 31, 2024                                                                                                  
  Q1 2023                                         140.5                        90.00      March 31, 2023          June 29, 2023     
  Q3 2023                                         148.0                        94.00      September 30, 2023      December 1, 2023  
  April 1, 2024, to March 31, 2025                                                                                                  
  Q1 2024                                         148.0                        94.00      March 31, 2024          June 27, 2024     
  Q3 2024                                         155.9                        98.00      September 30, 2024      December 2